Share Price Movements and Clinical Studies - Research Report on Celldex Therapeutics, Envision, MannKind, Covance, and Auxilium

   Share Price Movements and Clinical Studies - Research Report on Celldex
           Therapeutics, Envision, MannKind, Covance, and Auxilium

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 19, 2013

NEW YORK, December 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celldex
Therapeutics, Inc. (NYSE: CLDX), Envision Healthcare Holdings, Inc. (NYSE:
EVHC), MannKind Corp. (NASDAQ: MNKD), Covance Inc. (NYSE: CVD), and Auxilium
Pharmaceuticals Inc. (NASDAQ: AUXL). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Celldex Therapeutics, Inc. Research Report

On December 16, 2013, Celldex Therapeutics, Inc.'s (Celldex Therapeutics)
stock increased 5.28%, ending the day at $23.71. Over the previous three
trading sessions, shares of Celldex Therapeutics increased 7.53%, compared to
the Nasdaq Composite which increased 0.64% during the same period. The Full
Research Report on Celldex Therapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.AnalystsCorner.com/r/full_research_report/b443_CLDX

--

Envision Healthcare Holdings, Inc. Research Report

On December 16, 2013, Envision Healthcare Holdings, Inc.'s (Envision) stock
increased 2.68%, ending the day at $33.31. Over the previous three trading
sessions, shares of Envision increased 6.56%, compared to the Dow Jones
Industrial Average which advanced 0.26% during the same period. The Full
Research Report on Envision Healthcare Holdings, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4b31_EVHC

--

MannKind Corp. Research Report

On December 16, 2013, MannKind Corp.'s (MannKind) stock declined 0.40%, ending
the day at $4.96. Over the previous three trading sessions, shares of MannKind
increased 3.12%, compared to the Nasdaq Composite which went up 0.64% during
the same period. The Full Research Report on MannKind Corp. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/044e_MNKD

--

Covance Inc. Research Report

On December 16, 2013, Covance Inc.'s (Covance) stock declined 0.73%, ending
the day at $85.41. Over the previous three trading sessions, shares of Covance
increased 0.15%, compared to the Dow Jones Industrial Average, which gained
0.26% during the same period. The Full Research Report on Covance Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5691_CVD

--

Auxilium Pharmaceuticals Inc. Research Report

On December 13, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) announced that
the first patient was dosed in its Phase 2b study of collagenase clostridium
histolyticum (CCH) for the treatment of adult patients with adhesive
capsulitis, commonly known as Frozen Shoulder syndrome (FSS). Adrian Adams,
CEO and President of Auxilium, commented, "The initiation of our Phase 2b
Frozen Shoulder syndrome study represents another development milestone for
Auxilium as we further evolve our pipeline and advance a fourth potential
indication for CCH. We believe that our continued measured investments in
research and development, together with the upcoming product launches of
XIAFLEX in Peyronie's disease and STENDRA™ in erectile dysfunction, position
the Company well for growth and shareholder value creation." The Company
informed that Phase 2b study is a double-blind, placebo-controlled study of
the effectiveness and safety of CCH for the treatment of Stage 2 (frozen
stage) unilateral idiopathic FSS. Auxilium stated that the study will enroll
about 300 adult men and women at approximately 35 sites in the U.S. and
Australia wherein subjects will be randomized 3:1 to receive CCH or placebo
and will be given upto three ultrasound-guided injections of study drug. The
Company stated that each injection will be give after at least 21 days, and
all subjects will do home shoulder exercises following the first injection.
Auxilium added that Phase 2b study's primary endpoint is the change (degrees)
from baseline to the Day 95 follow-up visit in active forward flexion in the
affected shoulder compared to placebo. The Full Research Report on Auxilium
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/86a4_AUXL

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.